|
|
News Breaks | | | | November 14, 2012 | | 05:55 EDT |  | SPPI, SPPI, WAT, WAT, HSIC, HSIC, ISIS, ISIS, THOR, THOR, GWAY, GWAY, HRC, HRC, HWAY, HWAY, MYGN, MYGN, BMRN, BMRN, DRRX, DRRX, MCK, MCK | Credit Suisse to host a conference
2012 Healthcare Conference is being held in Phoenix on November 14-15. | |
|
News For MCK;DRRX;BMRN;MYGN;HWAY;HRC;GWAY;THOR;ISIS;HSIC;WAT;SPPI From The Last 14 Days Check below for free stories on MCK;DRRX;BMRN;MYGN;HWAY;HRC;GWAY;THOR;ISIS;HSIC;WAT;SPPI the last two weeks. |
|
|
| May 17, 2013 | | 08:04 EDT |  | THOR | Thoratec announces FDA approval of HeartMate II Pocket Controller
Thoratec announced that it has received approval from the FDA to market the HeartMate II Pocket Controller, the small, smart, safe face of the HeartMate II LVAD System. | | | May 16, 2013 | | 12:24 EDT |  | BMRN | On The Fly: Midday Wrap
The S&P 500 was virtually unchanged at midday following a deluge of domestic economic data this morning. The S&P began the session in negative territory, but only moderately lower, after investors received a host of data prior to the open, including reports on jobless claims, consumer prices, and housing starts. ECONOMIC EVENTS: In the U.S., initial jobless claims rose 32K to 360K last week, compared to expectations for them to remain relatively stable at 330K. The consumer price index dropped a larger than forecast 0.4% in April, though the "core" CPI rate rose 0.1%, as expected. Housing starts were down 16.5% in April from the prior month, versus an expected decrease of 6.4%, though building permits jumped 14.3% from the prior month, beating an expected increase of 3.8%. The Philadelphia Fed General Business Conditions Index for May came in at -5.2, versus expectations for a +2.2 reading. COMPANY NEWS: Earnings reports from two Dow members, Wal-Mart (WMT) and Cisco (CSCO), sent their shares in opposite directions. Cisco shares advanced 12% to lead the blue chip index after the company's results beat expectations on the top and bottom lines and prompted price target increases at several analyst firms. Wal-Mart, in contrast, lagged all Dow names, sliding 2% after its earnings for the just ended quarter and its view of the current quarter missed the consensus forecast... After the closing bell, Tesla Motors (TSLA) said it intends to raise about $830M by offering 2.7M common shares and $450M in convertible senior notes. CEO Elon Musk will buy $100M worth of the stock and debt, the company said, and its recently high-flying shares rose another 6%. MAJOR MOVERS: Among the notable gainers rising following Cisco's better than expected results and commentary were Ciena (CIEN), which rose 8%, and Cavium (CAVM), which advanced 4%. Also higher were shares of NetApp (NTAP), which gained over 6% after Bloomberg said activist investor Elliott Management has taken a stake in the company and is pushing its board to explore ways to boost shareholder value. Among the noteworthy losers were Oncothyreon (ONTY), which fell 20%, and Biomarin (BMRN), down 5%, after both pharmaceutical companies, among a number of others, published data to be presented at ASCO, an annual meeting of oncologists. Also lower was AMD (AMD), which declined 14% following a downgrade to Sell at Goldman Sachs. INDICES: Near noon, the Dow was up 12.47, or 0.08%, to 15,288.16; the Nasdaq was up 8.74, or 0.25%, to 3,480.36; and the S&P 500 was nearly flat at 1,658.80. | | | 11:50 EDT | | BMRN | Celgene, Gilead lower after new data published at ASCO
 Subscribe for More Information | | | 09:03 EDT |  | BMRN | BioMarin volatility low, shares near record high into ACSO
Subscribe for More Information | | | 08:33 EDT |  | BMRN | BioMarin abstract showed impressive anti-tumor activity, says Leerink
Subscribe for More Information | | | May 15, 2013 | | 19:34 EDT | | SPPI | On The Fly: After Hours Movers
Subscribe for More Information | | | 14:56 EDT | | MCK | McKesson has a conference call hosted by JPMorgan
Subscribe for More Information | | | 11:20 EDT | | MYGN | Options with increasing implied volatility: QCOR MYGN GDI
Subscribe for More Information | | | 11:16 EDT | | SPPI | Options with decreasing implied volatility: RAX CSC SPPI MBI PANL
| | | May 14, 2013 | | 12:02 EDT | | DRRX | Broadfin Capital reports 5.23% passive stake in DURECT
| | | | 12:00 EDT | | MYGN | Myriad Genetics climbs after Jolie reveals genetic testing
Subscribe for More Information | | | May 13, 2013 | | 10:09 EDT |  | THOR | On The Fly: Analyst Downgrade Summary
Subscribe for More Information | | | 07:39 EDT | | BMRN | BioMarin price target raised to $75 from $59 at Deutsche Bank
Deutsche Bank raised its price target for BioMarin citing increased value for the company's parp inhibitor. The firm keeps a Buy rating the stock. | | | 07:31 EDT | | THOR | Thoratec downgraded to Neutral from Buy at Lazard Capital
Subscribe for More Information | | | May 10, 2013 | | 09:21 EDT | | DRRX | On The Fly: Pre-market Movers
Subscribe for More Information | | | 07:46 EDT | | DRRX | DURECT says additional clinical studies needed for Remoxy
DURECT (DRRX) announced that Pfizer (PFE) has provided an update on Remoxy in a regulatory filing. Pfizer's disclosure included: "We have been working to address the issues raised in the letter, which primarily relate to manufacturing. We met with the FDA in March 2013 to discuss our plan to address the June 2011 "complete response" letter. We received written guidance from the FDA in May regarding required next steps, including additional clinical studies, to address the letter. Based on this guidance, we are considering our options with respect to Remoxy. If we elect to continue development of Remoxy, we would not expect to submit a response to the 'complete response' letter before mid-2015." DURECT said it understands from Pfizer that additional clinical studies are necessary and include, in part, a pivotal bioequivalence study with the modified formulation to bridge to the clinical data conducted with the original formulation, as well as an abuse potential study with the modified Remoxy formulation. Remoxy is based on DURECT's ORADUR technology. Shares of Pfizer's Remoxy partner Pain Therapeutics (PTIE) are down 56% in pre-market trading, while shares of DURECT are down 13%, or 20c, to $1.39. | | | 07:20 EDT | | MYGN | Myriad shares likely to rise after court decision, says RBC Capital
Subscribe for More Information | | | May 9, 2013 | | 16:59 EDT | | ISIS | Isis Pharmaceuticals earns $3.5M from Biogen
Subscribe for More Information | | | 11:15 EDT | | ISIS | High option volume stocks: BKS ISIS BRY GMCR JOE
| | | 10:08 EDT |  | MYGN | On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Chicago Bridge & Iron (CBI) initiated with a Buy at Deutsche Bank... Fluor (FLR) initiated with a Buy at Deutsche Bank... Infinity Pharmaceuticals (INFI) initiated with an Outperform at Wells Fargo... Jacobs Engineering (JEC) initiated with a Hold at Deutsche Bank... KBR (KBR) initiated with a Buy at Deutsche Bank... MasTec (MTZ) initiated with a Buy at Deutsche Bank... McDermott (MDR) initiated with a Hold at Deutsche Bank... Merit Medical (MMSI) initiated with a Hold at Benchmark Co... Ocean Power (OPTT) initiated with a Strong Buy at Ascendiant Capital... Quanta Services (PWR) initiated with a Buy at Deutsche Bank... ZELTIQ Aesthetics (ZLTQ) initiated with a Buy at Maxim... Evercore Partners (EVR) initiated with a Positive at Susquehanna... Alexander & Baldwin (ALEX) initiated with an Outperform at JMP Securities... Myriad Genetics (MYGN) coverage resumed with an Overweight at Stephens... Pinnacle Foods (PF) initiated with a Buy at Janney Capital. | | |
|
|
|
|
|
|
